These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39046277)

  • 1. An exploratory study of the efficacy and safety of amenamevir for the treatment of herpes zoster in patients receiving immunosuppressive drugs.
    Imafuku S; Takeuchi S; Urabe K; Arakawa M; Sasaki R; Oka D; Yamamoto T; Ono F; Shirahama S; Yasumoto S; Fukuda H
    J Dermatol; 2024 Oct; 51(10):1279-1289. PubMed ID: 39046277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study.
    Kawashima M; Nemoto O; Honda M; Watanabe D; Nakayama J; Imafuku S; Kato T; Katsuramaki T;
    J Dermatol; 2017 Nov; 44(11):1219-1227. PubMed ID: 28681394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient.
    Kobayashi H; Yoshida Y; Komoshita T; Suma H; Hosokawa Y; Hirose Y; Sugimoto T; Mokuda S; Hirata S; Sugiyama E
    Intern Med; 2022 Jun; 61(11):1785-1788. PubMed ID: 34776482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients.
    Tsuruoka S; Endo T; Seo M; Hashimoto N
    Adv Ther; 2020 Jul; 37(7):3234-3245. PubMed ID: 32440976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
    Kusawake T; Kowalski D; Takada A; Kato K; Katashima M; Keirns JJ; Lewand M; Lasseter KC; Marbury TC; Preston RA
    Adv Ther; 2017 Dec; 34(12):2612-2624. PubMed ID: 29134428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
    Shiraki K; Yasumoto S; Toyama N; Fukuda H
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
    Maeda H; Nakamura H; Kikukawa Y
    Nihon Yakurigaku Zasshi; 2019; 153(1):35-43. PubMed ID: 30643090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
    Kusawake T; Keirns JJ; Kowalski D; den Adel M; Groenendaal-van de Meent D; Takada A; Ohtsu Y; Katashima M
    Adv Ther; 2017 Dec; 34(12):2625-2637. PubMed ID: 29134426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
    Shiraki K
    Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Varicella-zoster meningoencephalitis and vasculitis after treatment with amenamevir to herpes zoster in the trigeminal nerve area].
    Taniguchi Y; Kano Y; Kitamura T; Miura T; Yamada K
    Rinsho Shinkeigaku; 2021 Apr; 61(4):239-242. PubMed ID: 33762495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aseptic Meningitis after Amenamevir Treatment for Herpes Zoster in the First Branch of the Trigeminal Nerve.
    Itoh K; Mitsuke Y; Wakahara M; Yoshioka T; Otsuki N; Suzuki Y; Kiriba C; Kuwata A; Sakamaki I; Iwasaki H; Tsutani H
    Intern Med; 2022 Sep; 61(18):2809-2811. PubMed ID: 35228415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case.
    Ishiguro A; Takama H; Yanagishita T; Ohshima Y; Watanabe D
    J Dermatol; 2019 Aug; 46(8):e270-e271. PubMed ID: 30897230
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older.
    Arora A; Mendoza N; Brantley J; Yates B; Dix L; Tyring S
    J Infect Dis; 2008 May; 197(9):1289-95. PubMed ID: 18422441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aseptic meningitis after amenamevir treatment for herpes zoster ophthalmicus with oculomotor nerve palsy in a patient taking immunosuppressant.
    Omiya M; Nishiguchi S; Moriya H; Akazawa K; Nagahiro T; Seto M
    J Infect Chemother; 2023 May; 29(5):519-522. PubMed ID: 36708771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster.
    Shoji N; Tanese K; Sasaki A; Horiuchi T; Utsuno Y; Fukuda K; Hoshino Y; Noda S; Minami H; Asakura W;
    J Dermatol; 2020 Jul; 47(7):683-688. PubMed ID: 32424854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.
    Gnann JW; Crumpacker CS; Lalezari JP; Smith JA; Tyring SK; Baum KF; Borucki MJ; Joseph WP; Mertz GJ; Steigbigel RT; Cloud GA; Soong SJ; Sherrill LC; DeHertogh DA; Whitley RJ
    Antimicrob Agents Chemother; 1998 May; 42(5):1139-45. PubMed ID: 9593141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
    Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
    J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
    Katsumata K; Chono K; Suzuki H
    Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir.
    Pacreau ML; Bomme O; Burrel S; Boutolleau D
    Antiviral Res; 2021 Nov; 195():105189. PubMed ID: 34666108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Drugs Against Alphaherpesvirus.
    Shiraki K
    Adv Exp Med Biol; 2018; 1045():103-122. PubMed ID: 29896665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.